Results 21 to 30 of about 4,828 (174)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia

Journal of Allergy and Clinical Immunology: Global, 2023
Background: Infants with respiratory-syncytial virus bronchiolitis hospitalization are more likely to develop wheezing and subsequent asthma. Reportedly, palivizumab prophylaxis effectively prevents respiratory-syncytial virus hospitalization in high ...
Li-Ching Fang, MD, Jen-Yu Wang, MD, Hsin-Hui Yu, MD, PhD, Li-Chieh Wang, MD, PhD, Bor-Luen Chiang, MD, PhD   +4 more
doaj   +1 more source

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

BMC Infectious Diseases, 2017
Background This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain. Methods A decision-tree
M. Sanchez-Luna, R. Burgos-Pol, I. Oyagüez, J. Figueras-Aloy, M. Sánchez-Solís, F. Martinón-Torres, X. Carbonell-Estrany   +6 more
doaj   +1 more source

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

Italian Journal of Pediatrics, 2009
Introduction The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.
Ravasio Roberto, Chirico Gaetano, Sbarigia Urbano   +2 more
doaj   +1 more source

Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia

Journal of Infection in Developing Countries, 2021
Introduction: Respiratory syncytial virus (RSV) is one of the most important childhood infections. Objective: To evaluate the effectiveness and safety of palivizumab immunoprophylaxis in preterm infants at a high risk of severe respiratory syncytial ...
Juan Gabriel Piñeros, Jose De la Hoz-Valle, Clara Galvis, Astrid Celis, Oscar Ovalle, Carmen Cecilia Sandoval, Jaime Orrego, Saby Vides, Iader Rojas, Hernando Bustamante, Carlos Gallón, Jaime Alberto Mesa   +11 more
doaj   +1 more source

Subcutaneous palivizumab (Synagis®) administration in an infant with congenital type 2B von Willebrand disease

Journal of Pediatric and Neonatal Individualized Medicine, 2015
Intramuscular injections are contra-indicated in infants with either acquired or congenital bleeding disorders. In such patients, it is unlicensed practice to administer vaccines by subcutaneous route.
Karel Allegaert, Maissa Rayyan, Veerle Cossey, Chris Van Geet   +3 more
doaj   +1 more source

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection

Scientific Reports, 2021
Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations.
Agata Antepowicz, Omar Habib, Freja Kirsebom, Cecilia Johansson, Deborah R. Gill, Stephen C. Hyde   +5 more
doaj   +1 more source

Predictive Value of Modified Lung Ultrasound Score for Late Respiratory Diseases in Premature Infants: A Retrospective Cohort Analysis

Journal of Clinical Ultrasound, EarlyView.
This study is to assess the predictive value of the modified lung ultrasound score (mLUS) for late respiratory diseases in premature infants born before 32 weeks of gestation. It is recommended that the use of mLUS scoring be promoted in clinical practice for the early screening of high‐risk preterm infants.
Shuang Zheng, Yang Zhang, Yanan Gao, Huifen Chen, Sudan Liu   +4 more
wiley   +1 more source

Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control

Medicinal Research Reviews, EarlyView.
ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi, Xiya Huang, Chunjun Ye, Yishan Lu, Yanyan Liu, Yuquan Wei, Xiawei Wei   +6 more
wiley   +1 more source

The influence of respiratory syncytial virus immunoprophylaxis on allergic sensitisation in children with respiratory allergy

Journal of Microbiology, Immunology and Infection
Background: Respiratory syncytial virus (RSV) infection may induce asthma and allergic sensitisation. RSV immunoprophylaxis can reduce the severity of RSV infections. However, the effects of RSV immunoprophylaxis on allergic sensitisation remains unclear.
Li-Ching Fang, Jen-Yu Wang
doaj   +1 more source

Trends in Hospitalisations Due to Respiratory Syncytial Virus in Swedish Children: A Nationwide Study 2010–2022

Acta Paediatrica, EarlyView.
ABSTRACT Aim Respiratory syncytial virus (RSV) infection is a leading cause of paediatric hospitalisations. This study describes annual RSV‐hospitalisation burden of disease, by gestational week of delivery, age and sex among children aged 0–17 years of age in Sweden, for the period 2010/11–2021/22.
Kristian Bolin, Karin Strandell, Andreas Palmborg, Sofie Gustafsson, Sven‐Arne Silfverdal   +4 more
wiley   +1 more source